Skip to content
Tablet Allopathic

Mavixen 100 mg+40 mg tablet

Generic: Glecaprevir + Pibrentasvir

Company: Everest Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength100 mg+40 mg
PackBox of 21: 84000.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated December 2, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Glecaprevir + Pibrentasvir 100 mg+40 mg tablets

Prices as listed on BestinMeds.

1 brand listed
Mavixen, box of 21 (this medicine)4000.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Glecaprevir + Pibrentasvir guide

Indications

Chronic hepatitis C This is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh ... Read more This is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). This is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

Dosage and administration

Testing Prior to the Initiation of Therapy: Test all patients for HBV infection by measuring HBsAg and anti-HBc. Recommended dosage: Three tablets (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) taken orally once daily with food. See recommended treatment duration in tables below- Treatment-Naïve Patients: HCV Genotype 1, 2, 3, 4, 5, or 6 No Cirrhosis: 8 weeks Compensated Cirrhosis (Child-Pugh A): 12 weeks Treatment-Experienced Patients: HCV Genotype 1 Patients Previously Treated With a Regimen Containing: An NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor No Cirrhosis: 16 weeks Compensated Cirrhosis (Child-Pugh A): 16 weeks Treatment-Experienced Patients: HCV Genotype 1 Patients Previously Treated With a Regimen Containing: An NS3/4A PI without prior treatment with an NS5A inhibitor No Cirrhosis: 12 weeks Compensated Cirrhosis (Child-Pugh A): 12 weeks Treatment-Experienced Patients: HCV Genotype 1, 2, 4, 5 or 6 Patients Previously Treated With a Regimen Containing: PRS No Cirrhosis: 8 weeks Compensated Cirrhosis (Child-Pugh A): 12 weeks Treatment-Experienced Patients: HCV Genotype 3 Patients Previously Treated With a Regimen Containing: PRS No Cirrhosis: 16 weeks Compensated Cirrhosis (Child-Pugh A): 16 weeks

Side effects

In subjects receiving this preparation, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue.

Precautions and warnings

Risk of Hepatitis B Virus Reactivation: Test all patients for evidence of current or prior HBV infection before initiation of HCV treatment. Monitor HCV/HBV coinfected patients for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

Pregnancy and lactation

No adequate human data are available to establish whether or not this preparation poses a risk to pregnancy outcomes. It is not known whether the components of this preparation are excreted in human breast milk, affect human milk production, or have effects on the breastfed infant. When administered to lactating rodents, the components of this preparation were present in milk, without effect on growth and development observed in the nursing pups. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for this preparation and any potential adverse effects on the breastfed child from this preparation or from the underlying maternal condition.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250